Zika Virus and Guillain–Barré Syndrome

  • Wilma González–Barreto
  • Gloria M. Rodriguez-Vega
  • Jorge Hidalgo
  • William Acevedo–Rosario


Zika is a virus transmitted primarily by the Aedes genus mosquito bites. Most people are asymptomatic or present with mild symptoms; however, after the Zika virus outbreak reported in several countries, an increase in the number of cases with neurological complications including Guillain-Barré syndrome were identified. Guillain-Barré syndrome is a rare immune-mediated neurological disorder characterized by rapid progression of symptoms including weakness, paralysis and in some cases death. Due to the wide spectreum of symptoms, early interventions are essential for a good prognosis and long term outcomes.


Zika virus Guillain-Barré syndrome 



Conflict of Interest: None declared.

Informed Consent: Informed consent was obtained from the individual for whom identifying information is included in this article.


  1. 1.
    Pan American Health Organization. Guidelines for surveillance of Zika virus disease and its complications. 2018th ed. Washington, DC: PAHO; 2018.Google Scholar
  2. 2.
    Adams L, Bello-Pagán M, Lozier M, et al. Update: ongoing Zika virus transmission–Puerto Rico. MMWR Morb Mortal Wkly Rep. 2016;65(30):774–9.CrossRefGoogle Scholar
  3. 3.
    Rabe IB, Staples JE, Villanueva J, et al. Interim guidance for interpretation of Zika virus antibody test results. MMWR Morb Mortal Wkly Rep. 2016;65:543–6.CrossRefGoogle Scholar
  4. 4.
    Centers for Disease Control and Prevention. Announcement: Guidance for U.S. Laboratory testing for Zika virus infection: implications for health care providers. MMWR Morb Mortal Wkly Rep. 2016;65(46):1304.CrossRefGoogle Scholar
  5. 5.
    Dirlikov E, Major CE, Mayshack M, et al. Guillain–Barré syndrome during ongoing Zika virus transmission – Puerto Rico, January 1–July 31, 2016. MMWR Morb Mortal Wkly Rep. 2016;65(34):910–4.CrossRefGoogle Scholar
  6. 6.
    Salinas JL, Major CG, Pastula DM, et al. Incidence and clinical characteristics of Guillain–Barré syndrome before the introduction of Zika virus in Puerto Rico. J Neurol Sci. 2017;377:102–6.CrossRefGoogle Scholar
  7. 7.
    Dirlikov E, Ryff KR, Torres-Aponte J, et al. Update: ongoing Zika virus transmission–Puerto Rico. MMWR Morb Mortal Wkly Rep. 2016;65(17):451–5.CrossRefGoogle Scholar
  8. 8.
    Hughes RA, Hadden RD, Gregson NA, Smith KJ. Pathogenesis of Guillain–Barre syndrome. J Neuroimmunol. 1999;100(1–2):74–97.CrossRefGoogle Scholar
  9. 9.
    Sejvar JJ, Kohl KS, Gidudu J, et al. Guillain–Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine. 2011;29(3):599–612.CrossRefGoogle Scholar
  10. 10.
    VM C–L, Blake A, Mons S, et al. Guillain–Barré syndrome outbreak associated with Zika virus infection in French Polynesia: a case–control study. Lancet. 2016;387(10027):1531–9.CrossRefGoogle Scholar
  11. 11.
    Dirlikov E, Medina NA, Major CG, et al. Acute zika virus infection as a risk factor for Guillain–Barré syndrome in Puerto Rico. JAMA. 2017;318(15):1498–500.CrossRefGoogle Scholar
  12. 12.
    Paz-Bailey G, Rosenberg ES, Doyle K, et al. Persistence of Zika virus in body fluids – final report. N Engl J Med. 2018;379(13):1234–43.CrossRefGoogle Scholar
  13. 13.
    Hennessey M, Fischer M, Staples JE. Zika virus spreads to new areas – region of the Americas, May 2015–January 2016. MMWR Morb Mortal Wkly Rep. 2016;65(3):55–8.CrossRefGoogle Scholar
  14. 14.
    World Health Organization. Assessment and management of Guillain–Barré syndrome in the context of Zika virus infection. Geneva: World Health Organization; 2016.;jsessionid=A23FAF9525EA100793D2E97ED452BA26?sequence=1Google Scholar
  15. 15.
    González-Barreto W, Rodríguez-Vega GM, De Jesus-Umpierre P, et al. Miller–Fisher–Guillain–Barré overlap syndrome during the Zika virus outbreak. Arch Clin Cases. 2017;4(4):199–203.CrossRefGoogle Scholar
  16. 16.
    Cherin P, Marie I, Michallet M, et al. Management of adverse events in the treatment of patients with immunoglobulin therapy: a review of evidence. Autoimmun Rev. 2016;15(1):71–81.CrossRefGoogle Scholar
  17. 17.
    Dirlikov E, Torres JV, Brasil Martines R, et al. Postmortem findings in patients with Guillain–Barré syndrome and Zika virus infection. Emerg Infect Dis. 2018;24(1):114–7.CrossRefGoogle Scholar
  18. 18.
    Yuki N, Hartung HP. Guillain–Barré syndrome. N Engl J Med. 2012;366(24):2294–304.CrossRefGoogle Scholar
  19. 19.
    Dirlikov E, Major CG, Medina NA, et al. Clinical features of Guillain–Barré syndrome with vs without Zika virus infection, Puerto Rico, 2016. JAMA Neurol. 2018;75(9):1089–97.CrossRefGoogle Scholar
  20. 20.
    Dos Santos T, Rodriguez A, Almiron M, et al. Zika virus and the Guillain–Barré syndrome—case series from seven countries. N Engl J Med. 2016;375(16):1598–601.CrossRefGoogle Scholar
  21. 21.
    Dirlikov E, Kniss K, Major C, et al. Guillain–Barré syndrome and healthcare needs during Zika virus transmission, Puerto Rico, 2016. Emerg Infect Dis. 2017;23(1):134–6.CrossRefGoogle Scholar
  22. 22.
    World Health Organization. Zika strategic response plan. Geneva: World Health Organization; 2016. Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Wilma González–Barreto
    • 1
  • Gloria M. Rodriguez-Vega
    • 2
  • Jorge Hidalgo
    • 3
  • William Acevedo–Rosario
    • 4
  1. 1.University of Puerto Rico, Medical Sciences CampusSan JuanPuerto Rico
  2. 2.Department of Critical Care MedicineHIMA–San PabloCaguasPuerto Rico
  3. 3.Division of Critical CareKarl Heusner Memorial Hospital/Belize Healthcare Partners Belize Central AmericaBelize CityBelize
  4. 4.VA Caribbean Healthcare SystemSan JuanPuerto Rico

Personalised recommendations